【我武生物：获得干细胞注射液药物临床试验批准通知书】我武生物公告称，公司间接控股子公司浙江我武干细胞科技有限公司提交的人脐带间充质干细胞II型注射液临床试验申请获国家药监局批准，该产品为治疗用生物制品1类，适应症为脓毒症和脓毒性休克。目前国内外尚无同适应症间充质干细胞药物获批上市，后续需完成I、II、III期临床试验及上市许可申请后方可上市，研发及上市存在较大不确定性。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.